Blockade of TNF-α activities with monoclonal antibodies (e.g. Infliximab, Adalimumab) as well as a receptor-immunoglobulin fusion protein (e.g. Etanercept) [3–5] significantly improved clinical outcomes, in particular, rheumatoid arthritis. This evidence concerns the gene TNF and rheumatoid arthritis.